Birgitte Volck

Birgitte Volck worked at Pharmexa A as Head-Clinical Development & Medical Affairs from 2001 to 2004.
From 2004 to 2007, worked at Genzyme Danmark as Director-Nordic Medical & Project Director.
From 2007 to 2012, worked at Amgen, Inc. as Director-Executive Development.
From 2012 to 2016, worked at Swedish Orphan Biovitrum AB as Chief Medical Officer & Senior VP-Development.
From 2016 to 2018, worked at GSK Plc as Head-Research & Development.
From 2016 to 2020, worked at TFS Trial Form Support AB as Non-Executive Director.
From 2017 to 2018, worked at Wilson Therapeutics AB as Independent Director.
From 2018 to 2020, worked at AVROBIO, Inc. as President-Research & Development.
From 2019 to 2026, worked at Soleno Therapeutics, Inc. as Independent Director.
From 2021 to 2023, worked at Ascendis Pharma A as SVP, Head-Clinical Development & Medical Affairs.
From 2021 to 2024, worked at Nykode Therapeutics ASA as Director.
From 2025 to 2026, worked at OMass Therapeutics Ltd. as Non-Executive Director.
Also worked at TFS Trial Form Support International AB as Director.
Education includes a doctorate from the University of Copenhagen.